Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits

por Weiss, Sidney L., Kramer, William G.
Publicado 2019

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of ster...

por Anglade, Eddy, Aspeslet, Launa J, Weiss, Sidney L
Publicado 2008

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease

por Tauber, Joseph, Schechter, Barry A, Bacharach, Jason, Toyos, Melissa M, Smyth-Medina, Robert, Weiss, Sidney L, Luchs, Jodi I
Publicado 2018

Sustained Release of Protein Therapeutics from Subcutaneous Thermosensitive Biocompatible and Biodegradable Pentablock Copolymers (PTSgels)

por Schaefer, Elizabeth, Abbaraju, Santhi, Walsh, Mary, Newman, Donna, Salmon, Jacklyn, Amin, Rasidul, Weiss, Sidney, Grau, Ulrich, Velagaleti, Poonam, Gilger, Brian
Publicado 2016

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers

por Karpecki, Paul M, Weiss, Sidney L, Kramer, William G, O’Connor, Patrick, Evans, David, Johnston, Josh, Jasper, April L, Justice, Angela, Ogundele, Abayomi B, Devries, Doug
Publicado 2019